Investigating the formation of abnormal amyloid fibrin clots in chronic and acute diseases
-
Researcher’s background in biochemistry and systems biology. • 1:33
-
Development of omix techniques and computer techniques for data analysis. • 2:01
-
Discovery of blood clotting into anomalous amyloid form. • 3:01
-
Use of thioflavin T stain to identify amyloid proteins in blood clots. • 3:38
-
Focus on microclots in chronic infectious diseases and long COVID. • 4:19
-
Collaboration with Risha Pretorius on research related to microclots. • 4:29
-
Discussion on the appearance of microclots under fluorescence. • 5:05
Study on abnormal clotting mechanisms in long COVID patients raises concerns about potential embalmers' clots
-
Different examples of people with long COVID showing abnormal clotting mechanisms. • 5:45
-
Implications of abnormal clotting in long COVID patients for treatment and management strategies. • 5:59
-
Need for further research to determine the percentage and specific mechanisms of abnormal clotting in these patients. • 7:05
-
Importance of understanding the mechanism behind the abnormal clotting in long COVID patients. • 7:13
-
Presence of abnormal clots that are more resistant to being dissolved due to malfunctioning clot removal mechanism. • 8:06
-
Speculation on the potential involvement of amyloid and prions in the abnormal clotting process. • 8:16
-
Discussion on the formation and breakdown of fibrin molecules in clotting process. • 8:31
Formation of amyloid fibrin clots may lead to serious health consequences such as embalmers' clots
-
Amyloid fibrin clots change conformation to be more resistant to fibrinolysis. • 09:24
-
Microclots can aggregate and lead to disseminated intravascular coagulation. • 10:02
-
Plasmin may be less effective in breaking down amyloid microclots. • 11:31
-
Triple treatment for long COVID helps prevent new clots but not remove existing ones. • 11:53
-
Microclots can form due to various factors like bacterial components binding to fibrinogen. • 13:01
Understanding the catalysts of fibrin clots formation in relation to infection and spike proteins
-
Infection and certain estrogens can trigger fibrin clot formation. • 13:25
-
Amyloid proteins catalyze the transformation into harmful forms. • 14:10
-
Presence of specific molecules can initiate fibrin clot formation. • 15:09
-
Demographics show differences in susceptibility to clotting mechanisms. • 16:35
-
Viral spike proteins are the main catalyst for clotting, regardless of source. • 17:25
-
Considerations on vaccine contents and their impact on clotting mechanisms. • 17:32
Understanding the complex factors contributing to potential clotting issues post-infection or vaccination
-
Individual reactions vary due to genetic and lifestyle factors. • 17:45
-
Observations of clotting issues post-infection or vaccination, with presence of Spike protein in immune cells. • 18:06
-
Potential mechanisms include circulating Spike protein, bacterial interactions, and interferon response. • 19:55
-
Discussion on conotoxins and toxin production by bacteria post-viral exposure. • 21:11
-
Hypothesis of multi-hit mechanism involving various triggers in clotting cascade. • 21:30
-
Role of interferon in managing latent viruses and potential impact on clotting issues. • 21:49
Understanding the potential impact of amyloid fibrin clots on blood vessels and clot formation
-
Interferon levels fluctuate, impacting clot formation. • 22:08
-
Spike protein triggers fibrinogen, leading to microclot formation. • 22:46
-
Microclots can join to form continuous sheets of clot. • 22:57
-
Lack of awareness about amyloid fibrin clots in the general population. • 23:29
-
Clots in venous blood are observable, but their impact and destination are uncertain. • 26:07